Core Insights - Moleculin Biotech, Inc. has been granted an Australian patent for preliposomal Annamycin lyophilizates, enhancing its global intellectual property portfolio with a base patent term extending until June 2040 [1][2] - Annamycin is being developed as a non-cardiotoxic anthracycline for treating acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases, with potential applications for various other cancers [2][4] - The company has initiated the MIRACLE trial, a Phase 3 study evaluating Annamycin in combination with cytarabine for relapsed or refractory AML, following a successful Phase 1B/2 study [5] Patent and Intellectual Property - The newly granted Australian patent covers preliposomal Annamycin with improved stability and high purity, contributing to the company's competitive position in oncology [1][2] - The patent family includes expected Canadian patents and previously issued U.S. and European patents, with additional applications pending in major jurisdictions worldwide [2] Drug Development and Clinical Trials - Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA for relapsed or refractory AML and STS lung metastases, as well as Orphan Drug Designation from the EMA [3] - The MIRACLE trial aims to evaluate the efficacy of Annamycin in combination with cytarabine, which is expected to de-risk the development pathway towards potential approval [5] Additional Pipeline Candidates - The company is also developing WP1066, an immune/transcription modulator targeting various cancers, and WP1122, an antimetabolite for treating pathogenic viruses and certain cancer indications [6]

Core Insights - Argo Corporation's Smart Routing™ system has led to a significant increase in monthly transfers at Bradford GO Station, with a 5.5x rise compared to the 12-month baseline prior to its launch in April 2025 [1][2] - The average total daily ridership in Bradford West Gwillimbury more than doubled within two months of the Smart Routing™ system's implementation, indicating its effectiveness in enhancing transit usage [2] - The integration of real-time GO Transit feeds and Ontario's PRESTO fare system further enhances the Smart Routing™ system's capability to improve existing transit infrastructure [2] Group 1 - The increase in connections to Bradford GO Station demonstrates the effectiveness of Argo's Smart Routing™ system in complementing existing public transit networks [1][2] - Public data indicates that in 2019, approximately 71% of GO customers accessed their origin station by car, highlighting the need for improved first/last-mile transit connections [3] - The growth in transit ridership benefits both riders and taxpayers by reducing personal car and rideshare costs while alleviating pressure on publicly-funded parking infrastructure [3] Group 2 - CEO Praveen Arichandran emphasized that the results in Bradford West Gwillimbury validate the company's vision for a future where public transit is the most convenient travel option [4] - Argo aims to create a vertically and publicly integrated city transit system that enhances public transportation and provides intelligently routed vehicles to meet urban mobility needs [4]

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MONTREAL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Osisko Development Corp. (NYSE: ODV, TSXV: ODV) ("Osisko Development" or the "Company") is pleased to announce the successful closing of its previously-announced oversubscribed private placement offering of 15,409,798 common shares of the Company (the "Common Shares") for aggregate gross proceeds of approximately C$82.5 million (the "Offering"). The Offering is compr ...

Company Overview - CYIOS Corporation LLC is a Nevada-registered holding company focused on acquisitions, modernization, and technology integration in the healthcare and medical supply sectors [1][5] - The company is actively expanding its presence in the U.S. medical distribution sector through its subsidiary Noir Medical Supplies, emphasizing operational excellence and sustainable profitability [5] Strategic Initiatives - CYIOS has engaged Atlanta Capital Partners, LLC to lead a renewed investor relations strategy aimed at enhancing visibility and communication within the investment community [1][4] - The current strategic plan includes reducing legacy debt, advancing targeted healthcare acquisitions, and scaling the AI-powered SaaS platform, CyioIQ [3] - The company aims to qualify for OTCQB and Nasdaq listings supported by a strengthened balance sheet [3] Growth and Transformation - The partnership with Atlanta Capital Partners is expected to elevate CYIOS's profile among investors seeking transformation-stage opportunities in high-demand sectors like healthcare technology [4] - Key initiatives under this partnership include expanded outreach to various investor types, consistent corporate updates, increased financial media exposure, and strategic event participation [4]

Kennewick, WA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) today announced enhanced cooperation with Exubrion Therapeutics to advance the use of targeted radioactive isotope technology for multiple indications in companion animals. The two companies have agreed to broaden their joint efforts in several key areas — including shared clinic relationships, licensing coordination, and manufacturing optimization. These initiatives build upon prior collaborations involving device classification, dev ...

Core Points - Aterian, Inc. announced the availability of its hOmeLabs brand line of dehumidifiers on Home Depot's website, enhancing its digital presence and sales strategy [1][3] - The hOmeLabs dehumidifiers are designed for improved health and efficiency, featuring user-friendly controls, Energy Star ratings, portability, and Wi-Fi capabilities [2] - Aterian aims to strengthen its brand presence and omni-channel sales approach through this partnership with Home Depot, a leading retail brand in the U.S. [3] Company Overview - Aterian, Inc. is a consumer products company that develops and acquires e-commerce brands across various categories, including home appliances and air quality devices [5] - The company sells products on major online marketplaces such as Amazon, Walmart, and Target, as well as through its own direct-to-consumer channels [5] - Aterian's brand portfolio includes well-known names like Mueller Living, PurSteam, hOmeLabs, and Squatty Potty [5] Home Depot Overview - Home Depot is the largest home improvement specialty retailer globally, operating over 2,353 retail stores and more than 325 distribution centers [4] - The company employs over 470,000 associates and is included in the Dow Jones Industrial Average and S&P 500 index [4]

PEKIN, Ill., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO) a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, announced it will release its third quarter 2025 financial results after the close of market on Wednesday, November 5, 2025. Management will host a conference call at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time and will deliver prepared remarks via webcast followed by a question-and-answer session. How to participate: To ...

Core Insights - Achieve Life Sciences, Inc. is focused on the development and commercialization of cytisinicline as a treatment for nicotine dependence and smoking cessation [1][3] - The company will report its Q3 2025 financial results and provide updates on the cytisinicline program on November 6, 2025 [1] - The FDA has accepted Achieve's New Drug Application for cytisinicline, with a PDUFA date set for June 20, 2026 [3] Company Overview - Achieve Life Sciences is a late-stage specialty pharmaceutical company addressing the global smoking health crisis through cytisinicline [3] - Cytisinicline has shown efficacy in two completed Phase 3 studies and an open-label safety study for smoking cessation [3] - The company has also completed a Phase 2 study for vaping cessation and had a successful end-of-Phase 2 meeting with the FDA [3] Industry Context - Approximately 29 million adults in the U.S. smoke combustible cigarettes, with tobacco use being the leading cause of preventable death [4] - There are around 17 million adults in the U.S. who use e-cigarettes, with no FDA-approved treatments specifically for nicotine e-cigarette cessation [5] - The FDA has recognized the need for treatments in this area by awarding a National Priority Voucher and granting Breakthrough Therapy designation [5] Product Information - Cytisinicline is a plant-based alkaloid that interacts with nicotinic acetylcholine receptors to help treat nicotine addiction [6] - The product is still investigational and has not yet received FDA approval for any indication in the U.S. [6]

Core Points - Alliance Entertainment Holding Corporation will hold a conference call on November 12, 2025, at 4:30 p.m. Eastern Time to discuss its Q1 fiscal year 2026 results [1] - The call will be hosted by CEO Jeff Walker, CFO Amanda Gnecco, and Executive Chairman Bruce Ogilvie, followed by a Q&A session [2] - The company is a leading distributor and logistics provider in the entertainment and pop culture collectibles industry, offering over 340,000 unique SKUs to more than 35,000 retail and e-commerce storefronts [4] Company Overview - Alliance Entertainment provides a vast selection of physical media, including over 57,300 exclusive titles across various formats such as CDs, vinyl LPs, DVDs, and video games [4] - The company also offers licensed merchandise, toys, retro gaming products, and collectibles, enhancing its position in the market [4] - Alliance's operational expertise and exclusive licensing partnerships enable it to serve as a trusted partner to top entertainment brands and retailers [4]

Core Insights - The Export-Import Bank of the United States (EXIM) has issued a $200 million Letter of Interest (LOI) to REalloys Inc., indicating potential support for a critical-minerals project under the China Transformational Exports Program (CTEP) [2][3][4] - This LOI highlights the U.S. government's commitment to establishing a secure, allied mine-to-magnet supply chain for rare-earth materials, aiming to reduce dependence on foreign sources and enhance industrial competitiveness [3][5][6] Company Overview - REalloys Inc. is focused on creating a vertically integrated North American supply chain for rare-earth materials, encompassing upstream resource development, midstream processing, and downstream manufacturing [8][10] - The company is advancing its Hoidas Lake project, which has a significant Mineral Resource Estimate of 2,153,000 tons of Total Rare Earth Oxides (TREO) [9][10] Financial Support and Strategic Importance - EXIM's LOI represents a potential financing opportunity of up to $200 million for REalloys' project capital expansion, with a provisional repayment term of up to 15 years [4][6] - The project aligns with U.S. government priorities to secure critical-materials supply chains essential for defense and advanced technologies, reflecting a broader strategy to enhance national security [5][6][7] Market Position and Future Prospects - REalloys aims to establish a fully Western-controlled rare-earth ecosystem, supported by long-term offtake agreements and strategic partnerships [8][10] - The company is also moving forward with a planned merger with Blackboxstocks Inc., positioning itself for accelerated growth in the North American rare-earth market [10]